Nuvectra (PRIVATE.NVTR)

Overall impact
B (68)

Commentary

Nuvectra is a strong overall performer. With a 'B' rating of 67.8 for overall impact (78th percentile compared to all companies), Nuvectra ranks 42nd out of 103 industry peers, behind MyMD Pharmaceuticals, Alphatec, electroCore and 38 others, and ahead of Waters, Biolase, Biomerica and 58 others. On top material causes for Nuvectra's industry (Healthcare Equipment), Nuvectra performs well in Child and Maternal Health (81.5 score), Humane Treatment of Animals (84.3), Improved Mental Health (89.4) and 3 other causes where it received an 'A' score and performs poorly in Disease Eradication (37.1 score) and Sanitation Access (25.9).
Impact
Cause PRIVATE.NVTR
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2008
Employees
200
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Texas, United States
Share classes
PRIVATE.NVTR
Description
Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes its neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets in Europe. The company's Algovita spinal cord stimulation system is used for the treatment of chronic pain of the trunk and limbs. It also provides neural interface technology, components, and systems, as well as NeuroNexus SmartBox portable control and data streaming systems. The company is based in Plano, Texas.
Material causes
Ethos considers the following causes material for Nuvectra, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.